Profile data is unavailable for this security.
About the company
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
- Revenue in GBP (TTM)882.33m
- Net income in GBP3.92m
- Incorporated2014
- Employees1.05k
- LocationIndivior PLC10710 Midlothian TurnpikeSuite 125, North ChesterfieldCHESTERFIELD 23235United StatesUSA
- Phone+0 (804) 379-1090
- Websitehttps://www.indivior.com/en
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotest AG | 665.95m | 150.53m | 1.16bn | 2.43k | 9.26 | 3.10 | -- | 1.74 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Fagron NV | 649.26m | 60.03m | 1.17bn | 3.46k | 19.47 | 2.96 | 12.77 | 1.81 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Genus plc | 673.10m | 33.40m | 1.19bn | 3.48k | 35.66 | 2.07 | 15.43 | 1.77 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Bonesupport Holding AB | 48.88m | 19.87m | 1.25bn | 121.00 | 62.89 | 29.54 | 60.34 | 25.50 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Evotec SE | 660.84m | -77.17m | 1.31bn | 5.06k | -- | 1.39 | -- | 1.98 | -0.5124 | -0.5124 | 4.39 | 6.24 | -- | -- | -- | 153,447.10 | -- | -0.0064 | -- | -0.0076 | 20.16 | 24.51 | -11.68 | -0.0178 | 1.79 | -2.09 | 0.3619 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 18.80m | -9.11m | 1.33bn | 90.00 | -- | 21.58 | -- | 70.85 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Galapagos NV | 249.67m | 26.13m | 1.44bn | 646.00 | 55.23 | 0.5859 | -- | 5.78 | 0.466 | 4.23 | 4.45 | 43.93 | 0.0653 | 0.1892 | 6.11 | 454,184.20 | 0.6829 | -1.48 | 0.7594 | -1.65 | 123.06 | -- | 10.47 | -14.42 | 9.70 | -- | 0.0028 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| Bavarian Nordic A/S | 758.14m | 112.36m | 1.65bn | 1.38k | 14.38 | 1.42 | 9.16 | 2.17 | 12.86 | 12.86 | 86.59 | 130.35 | 0.4956 | 1.74 | 9.32 | 4,816,359.00 | 7.35 | 1.21 | 8.92 | 1.48 | 60.90 | 53.72 | 14.82 | 4.06 | 1.03 | -- | 0.0427 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Dermapharm Holding SE | 948.73m | 48.15m | 1.68bn | 3.50k | 34.95 | 3.40 | 12.06 | 1.77 | 1.05 | 1.05 | 20.69 | 10.81 | 0.5137 | 1.25 | 9.68 | 318,823.00 | 2.51 | 8.68 | 3.01 | 10.06 | 63.32 | 61.94 | 4.89 | 12.31 | 0.7517 | 2.70 | 0.6367 | 54.69 | 10.79 | 14.68 | -53.54 | -3.70 | 9.85 | -- |
| Almirall SA | 774.28m | -32.99m | 1.78bn | 1.90k | -- | 1.39 | -- | 2.30 | -0.1797 | -0.1797 | 4.28 | 7.05 | 0.4107 | 1.51 | 6.15 | 477,897.10 | -1.75 | 0.922 | -1.97 | 1.08 | 75.56 | 78.06 | -4.26 | 2.48 | 1.94 | 12.34 | 0.1927 | -- | 3.62 | 3.40 | -998.72 | -- | -23.27 | -- |
| Vitrolife AB | 260.83m | -285.96m | 1.86bn | 1.13k | -- | 1.89 | -- | 7.15 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| BB BIOTECH AG | 235.53m | 267.72m | 1.93bn | -- | 7.11 | 0.8856 | -- | 8.17 | 5.62 | 5.62 | 4.91 | 45.11 | 0.0998 | -- | -- | -- | 11.35 | 2.34 | 12.96 | 2.52 | 97.74 | 99.06 | 113.67 | 35.40 | -- | -- | 0.1223 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| Indivior PLC | 882.33m | 3.92m | 1.95bn | 1.05k | 443.78 | 249.97 | 77.49 | 2.21 | -0.0162 | -0.0162 | 6.14 | 0.0578 | 0.7008 | 1.35 | 4.87 | 839,513.60 | 0.3117 | 1.32 | 0.7669 | 2.62 | 82.83 | 83.69 | 0.4448 | 2.68 | 0.7352 | -- | 0.9654 | 0.00 | 21.31 | 1.69 | 96.00 | -- | 5.27 | -- |
| MorphoSys AG | 173.17m | -388.32m | 2.20bn | 464.00 | -- | -- | -- | 12.72 | -12.54 | -12.65 | 5.79 | -6.95 | 0.1002 | 1.86 | 4.58 | 388,358.00 | -22.47 | -10.25 | -27.58 | -11.61 | 83.89 | 85.92 | -224.25 | -78.53 | 1.38 | -- | -- | -- | -14.37 | 25.53 | -25.60 | -- | 3.11 | -- |
| Camurus AB | 135.88m | 33.58m | 2.50bn | 218.00 | 74.58 | 12.65 | 72.02 | 18.37 | 7.79 | 7.79 | 31.75 | 45.91 | 0.8265 | 1.14 | 6.65 | 8,557,742.00 | 20.43 | -1.13 | 23.79 | -1.41 | 93.17 | 90.05 | 24.71 | -1.63 | 7.39 | -- | 0.0086 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| Virbac SA | 1.06bn | 103.22m | 2.58bn | 5.46k | 24.93 | 3.33 | 18.01 | 2.43 | 14.36 | 14.36 | 147.65 | 107.57 | 0.894 | 1.30 | 7.94 | 228,412.00 | 8.65 | 8.70 | 12.12 | 12.44 | 64.93 | 65.61 | 9.67 | 10.21 | 1.08 | 18.05 | 0.1166 | 7.21 | 2.53 | 7.49 | -0.5289 | 43.26 | 12.08 | -- |
Data as of May 31 2024. Currency figures normalised to Indivior PLC's reporting currency: UK Pound GBX
44.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Two Seas Capital LPas of 28 Mar 2024 | 13.56m | 10.01% |
| Morgan Stanley & Co. International Plcas of 31 Dec 2023 | 9.74m | 7.19% |
| Soci�t� G�n�rale Gestion SAas of 12 Apr 2024 | 6.48m | 4.79% |
| Scopia Capital Management LPas of 19 Mar 2024 | 6.29m | 4.65% |
| Madison Avenue Partners LPas of 14 Nov 2023 | 4.63m | 3.42% |
| The Vanguard Group, Inc.as of 30 Apr 2024 | 4.47m | 3.30% |
| BlackRock Investment Management (UK) Ltd.as of 30 May 2024 | 4.41m | 3.26% |
| Goldman Sachs Internationalas of 31 Mar 2024 | 4.22m | 3.12% |
| Fidelity Management & Research Co. LLCas of 30 Apr 2024 | 3.86m | 2.85% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.85m | 2.11% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
